Bremelanotide
CAS: 189691-06-3
Category: Peptides
| Purity | Pharmaceutical Grade (GMP-compliant, sterile, ≥98% by HPLC), Research Grade ≥95%, Analytical Referen |
| Molecular Formula | C₅₀H₆₈N₁₄O₁₀ |
| Molecular Weight | 1025.17 |
| Appearance | White to off-white lyophilized powder |
| Packaging | 1mg/2mg/5mg/10mg/vial (lyophilized for injection); autoinjector (1.75mg/0.3mL pre-filled device for subcutaneous injection, marketed as Vyleesi®); 25mg/50mg/bulk vial for research |
| Testing Indicators | Appearance — Visual inspection; Identification — HPLC-MS or MALDI-TOF; Purity — HPLC (C18 column, UV detection at 214–220 nm or 280 nm); Peptide content — Amino acid analysis or UV spectrophotometry (A280 for Trp/Tyr); Acetate content (counterion) — Ion chromatography; Water content — Karl Fischer titration; Residual solvents — GC; Bacterial endotoxins — LAL test; Sterility — Membrane filtration or direct inoculation (for pharmaceutical grade); Mass verification — Mass spectrometry (ESI or MALDI); Sequence verification — Edman degradation or MS/MS; Bioactivity — Melanophore assay (MC1R activation) or cAMP accumulation assay; Related substances (deamidated, oxidized, truncated, dimerized forms) — HPLC-MS; pH (reconstituted solution) — Potentiometry. |
| Storage Notes | Stored as lyophilized powder at 2–8°C (refrigerated) or -20°C for long-term storage; reconstituted solutions (with sterile water for injection) should be stored at 2–8°C and used within 7 days (per manufacturer Vyleesi® prescribing information); protect from light; do not freeze reconstituted solution; avoid repeated freeze-thaw cycles; away from heat, moisture, and proteases. |
| Lead Time | days |
Used as a pharmaceutical agent for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women (FDA-approved as Vyleesi®); acts as a non-selective melanocortin receptor agonist with high affinity for MC1R and MC4R, and moderate affinity for MC3R and MC5R; stimulates melanocortin receptors in the central nervous system (hypothalamus and limbic system) to modulate sexual desire and response; also studied for the treatment of erectile dysfunction (ED) in men (not approved); administered via subcutaneous injection approximately 45 minutes before anticipated sexual activity; exhibits pro-sexual, anorectic (appetite-suppressing), and melanogenic (skin darkening) effects as side effects.